Evidence map›Paper›PMID 39836259›Full record

ReviewMolecular biology reports2025

Exploring extracellular RNA as drivers of chemotherapy resistance in cancer.

Yumna Khan, Md Sadique Hussain, Prasanna Srinivasan Ramalingam, Rabab Fatima, Mudasir Maqbool, Sumel Ashique, Najeeb Ullah Khan, Ajay Singh Bisht, Gaurav Gupta

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Tumor-derived extracellular vesicles: Bridging communication and next-generation theranostics.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yumna KhanInstitute of Biotechnology and Genetic Engineering, The University of Agriculture Peshawar, Peshawar, PO Box 25130, Pakistan.
Md Sadique HussainUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, 248007, India. sadiquehussain007@gmail.com.
Prasanna Srinivasan RamalingamProtein Engineering Lab, School of Biosciences and Technology, Vellore Institute of Technology, Katpadi, Vellore, Tamil Nadu, 632014, India.
Rabab FatimaDepartment of Chemistry, Energy Acres, University of Petroleum & Energy Studies, Dehradun, Uttarakhand, 248007, India.
Mudasir MaqboolDepartment of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Jammu, Srinagar, Kashmir, 190006, India.
Sumel AshiqueSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Najeeb Ullah KhanInstitute of Biotechnology and Genetic Engineering, The University of Agriculture Peshawar, Peshawar, PO Box 25130, Pakistan.
Ajay Singh BishtSchool of Pharmaceutical Sciences, Shri Guru Ram Rai University, Patel Nagar, Dehradun, Uttarakhand, 248001, India.
Gaurav GuptaCentre for Research Impact & Outcome-Chitkara College of Pharmacy, Chitkara University, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy resistance (CR) represents one of the most important barriers to effective oncological therapy and often leads to ineffective intervention and unfavorable clinical prognosis. Emerging studies have emphasized the vital significance of extracellular RNA (exRNA) in influencing CR. This thorough assessment intends to explore the multifaceted contributions of exRNA, such as exosomal RNA, microRNAs, long non-coding RNAs, and circular RNAs, to CR in cancer. We discuss the mechanisms by which exRNA facilitates drug resistance, such as modulating gene expression, influencing the tumor microenvironment, and facilitating intercellular communication. Furthermore, we examine the potential of exRNA as prognostic factor for determining oncology treatment efficacy and their emerging role as therapeutic targets. Diagnostic and prognostic applications of exRNA biomarkers are considered, alongside current methodologies for their detection and quantification. Additionally, we review recent advances in exRNA-targeted therapies, highlighting ongoing clinical trials and therapeutic strategies aimed at overcoming chemoresistance. Despite the promise of exRNA research, several challenges remain, including technical limitations and the biological complexity of exRNA networks. This review underscores the importance of continued investigation into exRNA biology and its therapeutic potential, which in the future may provide new avenues for cancer treatment and tailored medical strategies. By elucidating the role of exRNA in CR, this article aims to provide a comprehensive resource for researchers and clinicians seeking to improve the effectiveness of carcinoma management approaches.

Indexed as

Drug Resistance, NeoplasmNeoplasmsBiomarkers, TumorExosomesGene Expression Regulation, NeoplasticHumansMicroRNAsPrognosisRNA, CircularRNA, Long NoncodingTumor MicroenvironmentBiomarkers, TumorMicroRNAsRNA, CircularRNA, Long NoncodingBiomarkersDrug resistanceExosomal RNAsExRNA-targeted therapyTumor microenvironment

Identifiers

PMID39836259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.